The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis.
Mice were protected against subsequent infection with Schistosoma mansoni by intradermal or s.c. vaccination with killed schistosomula or soluble parasite extracts and bacillus Calmette-Guérin (BCG). Treatment with i.p. immunization was somewhat less effective, whereas i.m. vaccination failed to elicit protective immunity. The level of resistance induced by intradermal immunization was influenced by the strain of BCG used, and isolated BCG cell walls did not reliably substitute for whole BCG organisms as adjuvant. Bordetella pertussis vaccine and saponin were also able to function as adjuvants for protective immunity in this model, whereas other immunopotentiators including Corynebacterium parvum and aluminum hydroxide were ineffective. No correlation between resistance to challenge infection and antibody levels was detected. Animals immunized intradermally using either protective or non-protective adjuvants all showed minimal humoral reactivity against schistosomulum surface Ag but strong IgG response to soluble parasite components including paramyosin, which is the major serologically recognized Ag in mice vaccinated intradermally with schistosome Ag plus BCG and is protective in this model. In contrast, a strong correlation was observed between resistance and Ag-specific cell-mediated reactivity, including IFN production by T lymphocytes in vitro and macrophage activation in vivo. These results further substantiate the hypothesis that protection in this model is based on cell-mediated immune effector mechanisms. Moreover, they may be of general relevance in the design of vaccination protocols using other Ag or against other infectious agents.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000534:Alum Compounds; D000535:Aluminum / Q000494:pharmacology; D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis*; D000947:Antigens, Helminth / Q000276:immunology; D001500:BCG Vaccine / Q000494:pharmacology*; D002473:Cell Wall / Q000276:immunology; D005260:Female; D005936:Glucans / Q000494:pharmacology; D007111:Immunity, Cellular; D007279:Injections, Subcutaneous; D007814:Larva; D051379:Mice; D008810:Mice, Inbred C57BL; D011425:Propionibacterium acnes / Q000276:immunology; D012503:Saponins / Q000494:pharmacology; D012550:Schistosoma mansoni / Q000254:growth & development / Q000276:immunology; D012555:Schistosomiasis mansoni / Q000517:prevention & control*; D013431:Sulfates / Q000494:pharmacology; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D001500:BCG Vaccine; D005936:Glucans; D012503:Saponins; D013431:Sulfates; D014612:Vaccines; C041524:aluminum sulfate; D000535:Aluminum